Welcome to our dedicated page for Almirall news (Ticker: LBTSF), a resource for investors and traders seeking the latest updates and insights on Almirall stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Almirall's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Almirall's position in the market.
Almirall reported its 2020 financial results amid challenges from COVID-19 and the genericization of Aczone®. Key figures include Net Sales of €807.4 MM, a decline of 5.4%, and Total Revenues of €814.5 MM, down 10.3%. The EBITDA decreased 21.7% to €238.3 MM. Despite this, the company plans for mid-single-digit growth in Core Net Sales and Core EBITDA guidance between €190-€210 MM for 2021. New CEO Gianfranco Nazzi aims to enhance growth prospects, with key product launches anticipated in 2021.
Almirall and MC2 Therapeutics announced a collaboration granting Almirall exclusive European commercialization rights for Wynzora® Cream, aimed at treating plaque psoriasis. MC2 Therapeutics will receive an upfront payment of EUR 15 million, milestone payments, and double-digit royalties on sales. The cream, already FDA-approved, is under European review with promising clinical trial results showing a 51% success rate in skin clearance. The collaboration targets a substantial market, with over 25 million units sold annually in Europe.
Almirall, S.A. announced the appointment of Gianfranco Nazzi as CEO and Executive Director, effective May 1, 2021. Nazzi joins from Teva Pharmaceuticals, where he held senior roles, including Executive VP of International Markets. His experience spans significant positions in major pharmaceutical companies like AstraZeneca and GSK. Jorge Gallardo, Chairman of Almirall, expressed confidence in Nazzi's leadership and vision for the company, emphasizing the focus on patient-centered solutions. This transition follows the departure of former CEO Peter Guenter on December 31, 2020.
Almirall, S.A., a global biopharmaceutical company based in Barcelona, has partnered with the University of Dundee to develop a new class of medicines targeting disease-causing proteins. This collaboration leverages Almirall's expertise in dermatology and Professor Alessio Ciulli's pioneering work on Targeted Protein Degraders (PROTACs). The goal is to innovate compounds for severe skin diseases with unmet medical needs. Almirall aims to advance drug discovery and enhance patient lives through this partnership, reflecting a commitment to transformative therapies.
FAQ
What is the current stock price of Almirall (LBTSF)?
What is the market cap of Almirall (LBTSF)?
